Crispr Therapeutics (NASDAQ:CRSP) and GENFIT S A/ADR (NASDAQ:GNFT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
This table compares Crispr Therapeutics and GENFIT S A/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|GENFIT S A/ADR||N/A||N/A||N/A|
This is a breakdown of recent ratings and recommmendations for Crispr Therapeutics and GENFIT S A/ADR, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|GENFIT S A/ADR||0||1||6||0||2.86|
Crispr Therapeutics currently has a consensus target price of $78.05, indicating a potential upside of 50.24%. GENFIT S A/ADR has a consensus target price of $47.89, indicating a potential upside of 181.56%. Given GENFIT S A/ADR’s higher probable upside, analysts clearly believe GENFIT S A/ADR is more favorable than Crispr Therapeutics.
Institutional & Insider Ownership
49.8% of Crispr Therapeutics shares are owned by institutional investors. Comparatively, 6.4% of GENFIT S A/ADR shares are owned by institutional investors. 21.4% of Crispr Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Crispr Therapeutics and GENFIT S A/ADR’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Crispr Therapeutics||$3.12 million||919.18||-$164.98 million||($3.44)||-15.10|
|GENFIT S A/ADR||$8.85 million||72.72||-$93.91 million||N/A||N/A|
GENFIT S A/ADR has higher revenue and earnings than Crispr Therapeutics.
GENFIT S A/ADR beats Crispr Therapeutics on 6 of the 11 factors compared between the two stocks.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
About GENFIT S A/ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.